Stay updated on Safety Efficacy Psilocybin Cancer Major Depressive Disorder Clinical Trial
Sign up to get notified when there's something new on the Safety Efficacy Psilocybin Cancer Major Depressive Disorder Clinical Trial page.

Latest updates to the Safety Efficacy Psilocybin Cancer Major Depressive Disorder Clinical Trial page
- Check2 days agoChange DetectedThe clinical trial record for a study of psilocybin in cancer patients with major depressive disorder is displayed, including study design, participation criteria, and outcome measures, replacing a forbidden-error page.SummaryDifference47%

- Check9 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check16 days agoChange DetectedA site-wide notice about NIH’s terminology transition appears above the ClinicalTrials.gov page, which still displays a 403 error instead of the study record.SummaryDifference1%

- Check23 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check30 days agoChange DetectedThe footer revision identifier was updated from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check51 days agoChange DetectedThe page now shows a 403 Forbidden error page with a minimal header and footer, replacing the previous study content and navigation.SummaryDifference19%

Stay in the know with updates to Safety Efficacy Psilocybin Cancer Major Depressive Disorder Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety Efficacy Psilocybin Cancer Major Depressive Disorder Clinical Trial page.